Is it just me, or seems like there are a bunch of “bots” leaving comments on BlueSky?

1-min video on Series A financing analysis in BioCentury. www.linkedin.com/posts/mattkr...

🎡 Zoltar meets predictive pharmacology? www.linkedin.com/posts/mattkr...

This BioCentury Inc. data will surprise you? A look at private biopharma raising Seed and Series A rounds over past 9 years. www.linkedin.com/posts/mattkr...

Monty Python fans out here? www.linkedin.com/posts/mattkr...

www.linkedin.com/posts/mattkr... Looking to see who is translating science into startups? BioCentury Inc.’s Danielle Golovin, Ph.D. spotlights several stealth-to-stage stories

$2.6B VC dispute threatening to sink stealth-mode biotechs? BioCentury’s Steve Usdin and Paul Bonanos unpack Apple Tree’s clash with Dmitry Rybolovlev, and what it could mean for its portfolio and the broader biotech ecosystem. 📄 Full analysis 👇 👇 👇 www.linkedin.com/posts/mattkr...

Wiffleball anyone? www.linkedin.com/posts/mattkr...

From my @biocentury.bsky.social colleague: www.linkedin.com/posts/mattkr...

One small step for cell surface targeting. One giant leap for solid tumor innovation... www.linkedin.com/posts/mattkr...

[ASCO]’ll be back www.linkedin.com/posts/mattkr...

🎤 EpCAM REVIVAL! lnkd.in/gGmJaq8W EpCAM is back on center stage. This time with conditionally activated ADCs, smarter bispecifics, and even CAR Ts? lnkd.in/gGmJaq8W

Are you a biopharma C-suite exec or investor dissecting rare disease playbooks? Then this one's for you. www.linkedin.com/posts/mattkr...

📉 How do you go from 15 scattered assets… to a $1B+ upfront deal? www.linkedin.com/posts/mattkr...

I'm curious. Who is your pick to be the HR leader for the 2025 season. Take the poll below. 👇 👇 👇 www.linkedin.com/posts/mattkr...

Is SMARCA2 the next KRAS moment for targeted protein degradation? www.linkedin.com/posts/mattkr...

I post a survey about what kinda curry you may like... and BOOM. Thing explodes. LOL Here's the link [LinkedIn]: www.linkedin.com/feed/update/...

🚨 New contender in the oral GLP-1 race 🚨 www.linkedin.com/posts/mattkr... (OPEN ACCESS) Ascletis Pharma Inc. ($1672.HK) just dropped early PIb data showing up to 6.5% placebo-adjusted weight loss in obese patients after 4 weeks on ASC30. By @biocentury.bsky.social's @stephenhansen.bsky.social

“Hey you guys!” – The Goonies Looking for a roadmap for how to handle Tariffs? BioCentury Inc.'s Simone Fishburn breaks down things you need to know in her latest report: "Tariffs are here — sweating the SWOT analysis" www.linkedin.com/posts/mattkr...

PERSONAL NOTE: 🌱 Need a break from doom-scrolling? Planting and prompting been working for me! 💻 - 2 things that help me stay grounded (literally and digitally): www.linkedin.com/posts/mattkr...

This is a pretty powerful piece! www.linkedin.com/posts/peterk...

Any radiophamra & Radiohead fans out here on Bluesky? If so, this one’s for you: www.linkedin.com/posts/mattkr...

🔊 ATTENTION: Innovation Hunters 🔊 🎥 lnkd.in/gpjDuvDC 🎥 Missed the latest @BioCentury Inc. Drug Development Disco 🪩 🪩 🪩 ? No worries—watch the recording.

His Death Was Interrupted, Just as He Had Planned. Brendan Costello’s family was bracing for goodbyes. But he had one last wish -- donating his organs, by @danbarry58.bsky.social www.nytimes.com/2025/03/16/n... #disability #transplant

I never truly understood the impact of organ donation until my cousin passed last month. Story starts with a successful kidney transplant for a psychiatrist who has saved countless others suffering from depression LI: www.linkedin.com/posts/mattkr... NYT: www.nytimes.com/2025/03/16/n...

Chasing Amy? Nah... How about Chasing Amylin? BioCentury dives into Roche’s $1.7B upfront bet on Zealand Pharma. 🔍 What’s in it for you? 1️⃣ Amylin is shaping up to be the next frontier in obesity drug development 2️⃣ Roche has skin in the game Details: www.biocentury.com/article/6553...

This took a couple of folks by surprise: "Bispecifics overtake ADCs in China deals" Recent BioCentury Inc. Data Graphic report from Lauren Martz dives in. Details and analysis here: www.biocentury.com/article/6552...

Great discussion of #biotech newco model at BioCentury's 4th East-West Biopharma Summit in Singapore, including leaders from Novo Holdings and Jeito, which just announced a newco with Singapore's Hummingbird last night. www.Biocenturyeastwest.com

The migration of MedTwitter, along with a large cohort of science journalists, to BlueSky is striking in its scale and rapidity. In a short time, this shift has effectively transformed BlueSky into the essential hub for breaking medical news and vibrant scientific discourse.

#GLP1 sales continue to boom thanks to #obesity market expansion #biosky #medsky www.biocentury.com/article/655202

Could amylin outshine GLP-1 in obesity? 🔬 Will amylin reshape the obesity treatment landscape? 📊 Sure feels that way. Novo, Lilly, and AZ are already in the game, and AbbVie just dropped $350M on an amylin asset. 📖 Access to the full report here: www.biocentury.com/article/6552...